Literature DB >> 29238896

Outcomes of Salvage Liver Transplantation and Re-resection/Radiofrequency Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma: A New Surgical Strategy Based on Recurrence Pattern.

Xiaoyun Zhang1, Chuan Li1, Tianfu Wen2, Wei Peng1, Lunan Yan1, Jiayin Yang1.   

Abstract

BACKGROUND: The treatment of intrahepatic recurrent hepatocellular carcinoma (HCC) has been poorly investigated, and the optimal treatment strategy remains unclear. AIMS: The aim of this study was to compare outcomes between salvage liver transplantation (SLT) and re-resection (RR)/radiofrequency ablation (RFA) for intrahepatic recurrent HCC according to recurrence pattern.
METHODS: Based on postoperative histopathological examination, 122 patients with intrahepatic recurrent HCC were divided into an intrahepatic metastasis (IM, n = 75) group and a multicentric occurrence (MO, n = 47) group. The demographic, clinical, and primary and recurrent tumor characteristics of the IM group and the MO group were collected and compared. Overall survival (OS) and disease-free survival (DFS) were analyzed, and subgroup analysis according to retreatment type (SLT vs. RR/RFA) was conducted. Twenty-nine clinicopathological variables potentially related to prognostic factors affecting survival were analyzed using a Cox proportional hazard model.
RESULTS: The patients that received SLT treatment exhibited favorable DFS compared to patients that received RR/RFA (P = 0.002). OS (P < 0.001) and DFS (P = 0.008) rates were significantly increased in the MO group compared with in the IM group. Subgroup analysis revealed that DFS was significantly improved for patients in the MO group treated with SLT compared to patients treated with RR/RFA (P = 0.017). Recurrence pattern was an independent prognostic factor for both OS [hazard ratio (HR) = 0.093, 95% confidence interval (CI): 0.026-0.337, P < 0.001] and DFS (HR = 0.318, 95% CI: 0.125-0.810, P = 0.016; HR = 3.334, 95% CI: 1.546-7.18, P = 0.002).
CONCLUSIONS: For patients with intrahepatic recurrent HCC, an MO recurrence pattern is associated with better long-term outcomes than the IM pattern. SLT is the preferred option for intrahepatic recurrent HCC, especially for MO cases.

Entities:  

Keywords:  Intrahepatic metastasis; Intrahepatic recurrence; Multicentric occurrence; Radiofrequency ablation; Re-resection; Salvage liver transplantation

Mesh:

Year:  2017        PMID: 29238896     DOI: 10.1007/s10620-017-4861-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients.

Authors:  Zheng-Gui Du; Yong-Gang Wei; Ke-Fei Chen; Bo Li
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2014-04

2.  Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis.

Authors:  P E Majno; F P Sarasin; G Mentha; A Hadengue
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

3.  Intratumoral genomic heterogeneity in human hepatocellular carcinoma detected by restriction landmark genomic scanning.

Authors:  R Saeki; H Nagai; S Kaneko; M Unoura; N Yamanaka; E Okamoto; K Kobayashi; K Matsubara
Journal:  J Hepatol       Date:  2000-07       Impact factor: 25.083

4.  Surgical treatment of recurrent hepatocellular carcinoma based on the mode of recurrence: repeat hepatic resection or ablation are good choices for patients with recurrent multicentric cancer.

Authors:  M Matsuda; H Fujii; H Kono; Y Matsumoto
Journal:  J Hepatobiliary Pancreat Surg       Date:  2001

5.  Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas.

Authors:  Osakuni Morimoto; Hiroaki Nagano; Masato Sakon; Yoshiyuki Fujiwara; Terumasa Yamada; Hidewaki Nakagawa; Atsushi Miyamoto; Motoi Kondo; Isao Arai; Tameyoshi Yamamoto; Hideo Ota; Keizo Dono; Koji Umeshita; Shoji Nakamori; Yo Sasaki; Osamu Ishikawa; Shingi Imaoka; Morito Monden
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

6.  Intratumor heterogeneity in hepatocellular carcinoma.

Authors:  Juliane Friemel; Markus Rechsteiner; Lukas Frick; Friederike Böhm; Kirsten Struckmann; Michèle Egger; Holger Moch; Mathias Heikenwalder; Achim Weber
Journal:  Clin Cancer Res       Date:  2014-09-23       Impact factor: 12.531

7.  Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection.

Authors:  Joana Ferrer-Fàbrega; Alejandro Forner; Alexandre Liccioni; Rosa Miquel; Víctor Molina; Miquel Navasa; Constantino Fondevila; Juan Carlos García-Valdecasas; Jordi Bruix; Josep Fuster
Journal:  Hepatology       Date:  2016-01-13       Impact factor: 17.425

8.  Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study.

Authors:  K Takenaka; E Adachi; T Nishizaki; K Hiroshige; T Ikeda; M Tsuneyoshi; K Sugimachi
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

9.  Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.

Authors:  Young-Joo Jin; Jin-Woo Lee; Oh Hyun Lee; Hyun Jung Chung; Young Soo Kim; Jung Il Lee; Soon Gu Cho; Yong Sun Jeon; Kun Young Lee; Seung-Ik Ahn; Woo Young Shin
Journal:  J Gastroenterol Hepatol       Date:  2014-05       Impact factor: 4.029

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  1 in total

1.  Sorafenib with or without concurrent transarterial chemoembolization in hepatocellular carcinoma: a cautionary comment of STAH trial.

Authors:  Jia-Hao Chen; Xu Liu; Kang Chen; Xiao-Yin Hu; Bang-De Xiang; Wei-Ping Yuan
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.